
News|Videos|June 8, 2018
Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
Author(s)Apar Kishor Ganti, MD, MS
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
2
Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment
3
How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies?
4
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC
5


















































































